HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.
Mentioned
Related Signal
Adjacent reporting
- Some U.S. employers are dropping weight loss drug coverage as use surges
- US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
- Restrictions on obesity drug coverage force patients to pivot
- This CEO wants to cover weight loss drugs for employees. They're just too expensive.
- STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
- Weight loss drugs GLP-1s are shifting fashion and food trends